The U.S. Food and Drug Administration recently approved Cresemba (isavuconazonium sulfate), a new antifungal drug product used to treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections. Cresemba belongs to a class of drugs called azole antifungal agents, which target the cell wall of a fungus.
A new antibacterial drug, Avycaz (ceftazidime-avibactam), was also recently approved by the FDA to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from the FDA and Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
Product Removal/Foodborne Illness Outbreak Investigation Advisory (March 18, 2015)
CDC and Partners Investigate Newly Discovered Virus (February 20, 2015)
FDA Approves a Second Vaccine to Prevent Serogroup B Meningococcal Disease (January 23, 2015)
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)
Is Your Facility Experiencing Antibiotic Shortages?
IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at firstname.lastname@example.org.
< Previous Article | Next Article >